Company intelligence / Profile preview

Indigo Pharmaceuticals

New York City, New York, United Statesdnb.com ↗

Ownership: Private
Development stage: Other

Overview

Indigo Pharmaceuticals focused on developing new treatments for cardiovascular diseases. Its main known asset was INDI-702, licensed from Nissan Chemical Industries and Taisho Pharmaceutical Co. for arteriosclerosis obliterans. No recent clinical results or commercial products are reported; the company is now out of business[2][6][8].

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Nissan Chemical IndustriesTaisho Pharmaceutical Co.

Beyond the preview

Go deeper on Indigo Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indigo Pharmaceuticals.

Explore the full profile